Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences pays off its convertible variable debt

The repayment eliminates the threat of shareholder dilution.
Pressure BioSciences pays off its convertible variable debt
Funds raised have been used to increase marketing spend

Pressure BioSciences (OTCQB:PBIO) has paid off all of its outstanding variable convertible debt after the fourth round of a US$5mln funding pulled in US$730,000.

Pressure, which provides technology for the preparation stage of lab testing in life science research, has now raised US$4.76mln, with one more offering likely to meet the US$5mln target.

The additional funds mean Pressure has been able to eliminate all convertible debt, which was one of the major objectives of the funding, said Richard Schumacher, chief executive, 

After fees, the fourth round netted the company US $657,000.

"With the funds raised to date, we have successfully completed the number one goal of the offering: the elimination of 100% of the company's variable rate (floorless) convertible debt,” said Schumacher.

“Since the initial close of the offering in July 2015, we have paid off approximately US$2.7mln of variable rate loans.

“Although we have never allowed any of this debt to convert under the terms of the loans, I am certain it is very comforting to all stakeholders in PBI to know that all of these loans are now completely paid off."

Schumacher added: "Funds received in the offering have also been used for important and timely operating activities.

“Specifically, we have begun to expand our marketing and sales areas while concomitantly increasing our manufacturing and other operating capabilities."

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use